Kev Dhaliwal's group investigates Disruptive Optical Technologies to Advance Respiratory Medicine and Critical Care.
Current disease modelling and biological strategies for intervention are hampered by the lack of incisive molecular methodologies that define disease pathogenesis in vivo in situ in real human disease. Molecular Imaging is a rapidly evolving multidisciplinary field that has the potential to revolutionise the practice of medicine and redefine the discipline of pathology.
Our group is multidisciplinary and has two broad themes 1) Focused on discovering new methodologies that will permit the accurate and spatial characterisation of inflammation, infection and fibrosis in the distal human lung. We work alongside chemistry, physics, engineering, image analysis and informatics to develop optical molecular imaging strategies; 2) Understanding the pulmonary response to acute infection and inflammation with a particular interest in monocyte/macrophage biology and neutrophil recruitment.
Current research projects in the lab are focused upon:
a) Developing novel point of care diagnostics for bacterial detection in the distal lung
b) Developing novel point of care drug stratification tools for Acute Lung Injury
c) Developing novel point of care tools to monitor the fibroproliferative pathway
d) Characterising fibroproliferative disease that occurs spontaneously in animals to reduce, refine and replace animal experimentation
e) Determining the role of monocytes in pulmonary inflammation secondary to head injury
f) Antibacterial and antituberculous activity of small synthetic peptidomimetics
g) Understanding and defining the contribution of damage-associated molecular pattern molecules in pulmonary infection and organ injury
A major new programme of work was initiated in October 2013 in our group in the QMRI to host and lead the 'hub' of an EPSRC Interdisciplinary Research Collaboration funded programme entitled "Touch and Tell Optical Molecular Sensing and Imaging". The 'hub' brings together physicists, biologists, informaticians, image analysts, chemists and engineers with the goal to develop a novel transformative device for monitoring blood and the distal human lung in critical care environments.
Professor Kev Dhaliwal graduated from the University of Edinburgh and completed general professional training in London before returning to Edinburgh to undertake a period of consolidated laboratory research in the Lung Inflammation Group. During his PhD he developed close links with the Department of Chemistry (Professor Mark Bradley) and, along with Professor Chris Haslett, the group initiated a startegic partnership to develop and translate optical molecular imaging in pulmonary disease. Professor Dhaliwal completed specialist training in Respiratory Medicine and was employed as a Senior Clinical Lecturer in Pulmonary Molecular Imaging in 2013. He leads a translational group working across multiple disciplines with an ethos of 'molecule to man'.
Active Clinician with a clinical subspecialty interest in Tuberculosis.
Cofounder of Edinburgh Molecular Imaging. EMI is a CIR spin-out company based upon the world‐class translational research (spanning chemistry, biology, and medicine) of its three founders from the University of Edinburgh: Professor Mark Bradley (School of Chemistry), Professor Chris Haslett and Professor Kev Dhaliwal (College of Medicine and Veterinary Medicine).
Dr Manuelle Debunne - Postdoctoral Scientist now pursuing a Saltire Fellowship
Primary School Outreach